DiaGenic continues efforts to find a financial solution

It is referred to the announcement made on 28 October 2013 regarding the financial situation of DiaGenic ASA (the “Company”).

The new board of directors, as elected by the EGM held on 22 November 2013, is continuing the efforts to find a financial solution for DiaGenic ASA. Further communication has been initiated with the Company’s largest creditors in order to find solutions for the best of all stakeholders and reduce the Company’s financial liabilities going forward. If no such voluntarily solutions are found within short, the board of directors will have to evaluate the immediate future of the Company.

For more information, contact:Hanne Skaarberg Holen, Chairman of the board, telephone: +47 9829 4591

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com